FeesSafety
Pluang+

Coastal Financial posts $13.8M Q3 net income, driven by strong BaaS growth and partner expansion.

Company Fundamentals
29 Oct 2026, 13:30 WIB
GlobeNewsWire
View Source
Bullish
Coastal Financial posts $13.8M Q3 net income, driven by strong BaaS growth and partner expansion.

Coastal Financial Corporation reported a net income of $13.8 million for Q3 2026, rebounding from a loss in Q2 due to strong growth in its banking-as-a-service (BaaS) segment, CCBX. Fee income from the BaaS program increased 17.6% quarter-over-quarter, supported by expanding partner relationships and product diversification. The company also saw a 4% deposit growth in its community bank segment, maintaining strong capital and liquidity positions. Coastal expects continued growth from new partnerships and product launches, while focusing on operational efficiency and risk management.

Coastal Financial Corporation's Q3 2026 results provide context for readers, with Pluang's snapshot as of Oct 29, 2026 17:11 WIB showing breadth among 142 priced Financials-sector US stocks where 80 rose and 56 fell. Notable movers include LYG at USD 5.27 with a 1-day change of -4.18% and Pluang order activity fully on the sell side, GLXY at USD 18.32 down 4.03%, and HUT at USD 66.88 down 3.71%. The most notable figure is LYG's 100% sell order activity on Pluang.

More News

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...

Market News
Bullish
1 hour ago
Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...

Company Fundamentals
Bullish
1 hour ago
Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...

Others
Bullish
2 hours ago
Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...

Market News
Neutral
2 hours ago
Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App